MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...

Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year. With a data cutoff date of August 1, 2024, 16 patients had a survival follow-up period of more ...

MAIA Biotechnology Inc. (AMEX: MAIA), the clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, completed enrollment for its phase 2 trial for THIO, its lead therapy ...

THIO combined with Libtayo shows improved progression-free survival of 5.6 months versus 2.5 months with standard treatments in advanced non-small cell lung cancer. The THIO-101 trial indicates a ...

Selected dose shows unprecedented disease control and overall response rates in a NSCLC clinical trial CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the ...

THIO, a first-in-class agent, targets telomeres, inducing cancer cell death and activating immune responses in NSCLC. The THIO-101 trial showed a median overall survival of 16.9 months, surpassing ...

Study showed THIO with complete and durable responses in Hepatocellular Carcinoma (HCC), or the dominate histology in primary liver cancer (90%), in vivo models When combined with immunotherapy ...

MAIA Biotechnology has activated a new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for the Phase II THIO-101 expansion trial. The study aims to evaluate the ...

Contrary to normal breast cells, breast tumour cells and breast cancer cell lines continue to proliferate and give rise to larger acini with altered external morphology and no central lumen owing to ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer ...

A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701). Background: The nucleoside analog 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) ...